Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients.

COVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP in a propensity-matched analysis, and whether the presence of antibodies in the recipient at the time of treatment or the titer of...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Carlo J Iasella, Stefanie J Hannan, Emily J Lyons, Sophia C Lieber, Antu Das, Dimiter Dimitrov, Wei Li, Melissa Saul, Iulia Popescu, Ritchie Koshy, Robin Burke, Braidon Lape, Mark J Brown, Xiaoping Chen, John C Sembrat, Kaitlyn Devonshire, Georgios D Kitsios, Ioannis Konstantinidis, Mark E Snyder, Bill B Chen, Christian A Merlo, David N Hager, Joseph E Kiss, Mark H Yazer, Alan H Wells, Alison Morris, Bryan J McVerry, Deborah K McMahon, Darrell J Triulzi, John F McDyer
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Public Library of Science (PLoS) 2024-01-01
Rangatū:	PLoS ONE
Urunga tuihono:	https://doi.org/10.1371/journal.pone.0309449
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!